Free tool
Rare disease stocks
We cover 7 companies grouped under the Rare disease theme. The median market value in the group is $3.12B. Across the group, the median move over the past trading day is +0.60%. Price change over the past year runs from −32.6% to +204.3% across the middle 80 percent of the group, with a median of +48.9%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
7 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| BMRN | BioMarin Pharmaceutical Inc. | $12.70B | Large cap | +11.85% | Oct 26, 2026 |
| ABVX.PA | ABIVAX Société Anonyme | $10.21B | Large cap | +48.91% | Sep 21, 2026 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% | Oct 27, 2026 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +60.64% | Oct 27, 2026 |
| GNFT.PA | Genfit S.A. | $830.56M | Small cap | +310.45% | Sep 29, 2026 |
| RZLT | Rezolute, Inc. | $485.31M | Small cap | −30.00% | Sep 16, 2026 |
| INM | InMed Pharmaceuticals Inc. | $7.64M | Micro cap | −36.44% | Sep 23, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.